Celcuity (CELC) Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

Go back to Celcuity (CELC) Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

March 16, 2021 4:00 PM EDT

- Trial will evaluate the efficacy and safety of Novartis targeted therapy TABRECTA® and Pumas NERLYNX® in patients with metastatic HER2-negative breast cancer selected by Celcuitys CELsignia Multi-Pathway Activity Test

- This is Celcuitys second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies

- Five clinical trial collaborations are now in place and include ones with Genentech, Pfizer, Novartis and Puma

MINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology... More